|
|
| Home | Stock Market Blogs | Financial Tools | Sign Up Free | |
| MultiCell Technologies, Inc. | |
||||||||||||||||||||||||||||||||||||||||||||||||||||
| MultiCell Technologies, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCET | Last: $0.0072 ($+0.0005) | Volume: 1,301,100 | Last Trade: 7/30/2010 2:07:25 PM | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Today
Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| MultiCell Technologies, Inc. Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| MultiCell Technologies is an integrated biopharmaceutical company engaged in pursuing research and development targeting degenerative neurological diseases, including multiple sclerosis (MS), metabolic and endocrinological disorders, including Type-1 diabetes, infectious diseases, including hepatitis, sepsis and influenza and degenerative ocular diseases, including macular degeneration. As of Nov 30 2006, Co.'s therapeutic pipeline includes MCT-125, directed at treating chronic fatigue in MS patients; MCT-175, targeting relapsing-remitting MS; MCT-275, for the treatment of type-1 diabetes, and MCT-465, an adjuvant therapy for the treatment of influenza A infections. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| MultiCell Technologies, Inc. News & Press Releases | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
BUYINS.NET: SGMO, TMCV, BMRX, MCET, GWLK, HESG Have Been On BUYINS ... Trading Markets (press release): BUYINS.NET: SGMO, TMCV, BMRX, MCET, GWLK, HESG Have Been On BUYINS ... , CA - Mar 17, 2008 MultiCell Technologies Inc. ( OTCBB: MCET | news | PowerRating | PR Charts ) a biopharmaceutical company, develops and commercializes therapeu MultiCell Signs License Agreement With Eisai Japan to Use Fa2N-4 ... PR Newswire (press release): MultiCell Technologies, Inc. ( OTC Bulletin Board: MCET ), has executed a five year licensing agreement with ... MultiCell Technologies Signs Key Formulation and Supply Agreement ... MacReport (press release): (MARKET WIRE) -- April 18, 2007 -- MultiCell Technologies, Inc. ( OTCBB: MCET ) has entered into an agreement with Merck KGaA & Co. ... MultiCell announces formulation and supply deal with Merck San Diego Daily Transcript (subscription): , CA - Apr 18, 2007 MultiCell Technologies Inc. ( OTCBB: MCET ) announced Wednesday that it has entered into an agreement with Merck KGaA & Co. Spittal/Drau Austria for the ... MultiCell inks deal with drug-component Providence Business News: , RI - Apr 18, 2007 MultiCell Technologies Inc. ( OTC BB: MCET .OB) is a biopharmaceutical company focusing on the development of new drugs and drug-development technologies. ... What side of the Stem Cell ''Fence'' are you on? Market News First Financial News: , TX - Apr 12, 2007 ... MultiCell Technologies Inc. ( OTCBB: MCET ); Endovasc Inc. (OTCBB: EVSC); BioStem Inc. (OTCBB: BTEM); ViaCell Inc. (Nasdaq: VIAC) and Opexa Therapeutics, ... MultiCell Technologies Signs Key Supply Agreement With Lundbeck ... MacReport (press release): MultiCell Technologies, Inc. ( OTCBB: MCET ) has entered into a long-term agreement with Lundbeck Pharmaceuticals Italy SpA for the supply ... MultiCell enters supply agreement with Italian drug manufacturer San Diego Daily Transcript (subscription): , CA - Apr 9, 2007 MultiCell Technologies Inc. ( OTCBB: MCET ) has entered into a long-term agreement with Lundbeck Pharmaceuticals Italy SpA for the supply of one of the active ... |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign Up | Copyright © 2010 SmallCapWatch, LLC. |
| Never invest based soley on information from this website or our e-mail and IM alerts | |
